Pathogenesis and progression of acute myeloid leukemia (AML) critically involved aberrant glycogen metabolism. AML is a heterogeneous disorder of hematopoietic stem cells characterized by the uncontrolled proliferation of aberrant clones of myeloid progenitor cells with impaired differentiation and by suppressed production of healthy hematopoietic cells. The pathogenesis of AML involves two types of gene mutations. Additionally, a third class of genes encoding epigenetic modifiers is found to play a major role in leukemogenesis.
Fig.1 Targeting glycogen metabolism as a strategy in cancer therapy. (Zois & Harris, 2016)
Abnormal glycosylation in a variety of cancer types is involved in tumor progression and chemoresistance. Glycogen metabolism has become an important aspect of cancer cell pathophysiology. At the aspect of both genetics and the function of the cells that make up the disease, AMLs are heterogeneous with respect.
Fig.2 Glycogene discovery methods in leukemia. (CD BioGlyco)
CD BioGlyco is a disseminator and leader of Glycogenomics, and we are committing to meet the market demand for Cancer Glycogene research. Our expert team has extensive experience in Glycogene Editing, Glycogene Delivery, and Glycogene Expression Profiling. Please feel free to contact us if you need services.